706820-94-2Relevant academic research and scientific papers
Efforts toward oral bioavailability in factor VIIa inhibitors
Vijaykumar, Dange,Rai, Roopa,Shaghafi, Michael,Ton, Tony,Torkelson, Steve,Leahy, Ellen M.,Riggs, Jennifer R.,Hu, Huiyong,Sprengeler, Paul A.,Shrader, William D.,O'Bryan, Colin,Cabuslay, Ronnell,Sanford, Ellen,Gjerstadt, Erik,Liu, Liang,Sukbuntherng, Juthamas,Young, Wendy B.
, p. 3829 - 3832 (2007/10/03)
Efforts toward developing orally bioavailable factor VIIa inhibitors starting from parenteral lead compound 1 are described. SAR resulted in improved physicochemical properties, leading to enhanced oral absorption in rat.
2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS
-
Page 76, (2008/06/13)
The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
